Drug

Dicumarol

As of the edition of 20 October 2026, Dicumarol is a small molecule: marketed, first approved in 1982 (US); acts on VKORC1; no US protection is listed.

Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.

The drug

Status
Marketed; latest approval 1982
Kind
Small molecule
First approved
1 January 1982 (US)
Approvals on record
5 in 1 region
Holder of the most recent approval
AbbVie; 2 holders in all
Registered trials
1, 0 stopped early
Disease areas
Heart and blood vessels; Injuries; Nervous system

US protection

No US protection is listed.

The FDA registers list no drug-substance patent or exclusivity that counts for this drug.

This is the US only.

Target

GeneProteinUniProt
VKORC1Vitamin K epoxide reductase complex subunit 1Q9BQB6

Registered trials

PhaseTrialsCompletedActiveStopped early
Phase not stated1100
All trials1

Who has held its approvals

CompanyRoleYears
AbbVieAcquired holder2012 to now
AbbottLater holder
Eli LillyApplicant